Marlborough drugmaker Sunovion Pharmaceuticals announced Thursday that clinical tests for its new drug to treat adolescents with schizophrenia is showing positive signs.
Sunovion said a six-week study of the drug Latuda showed statistically significant improvement in symptoms of young adults suffering from the mental health disease. Test subjects were given either a lower dose of 40 milligrams per day, a higher dose of 80 milligrams per day or a placebo.
In addition to treating symptoms, Latuda was generally well tolerated by both dose groups with 16 percent showing drowsiness, 13 percent showing nausea, 9 percent experiencing restlessness and 8 percent reporting vomiting.
